Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy

Journal of Clinical Oncology

Volumn 29, Issue 21, 2011, Pages 2852-2858

  Abdulkarim, Bassam S ^a   Cuartero, Julie ^a   Hanson, John ^a   Deschênes, Jean ^a   Lesniak, David ^a   Sabri, Siham ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RELAPSE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MASTECTOMY; MODIFIED RADICAL MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ALBERTA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79960714832     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4714     Document Type: Article

References (31)

1. Fisher B, Anderson S, Bryant J, et al: Twentyyear follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002 (Pubitemid 35176242)
2. Veronesi U, Cascinelli N, Mariani L, et al: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002 (Pubitemid 35176241)
3. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005
4. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
5. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
6. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006 (Pubitemid 43854964)
7. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol 26:2373-2378, 2008
8. Kyndi M, Sørensen FB, Knudsen H, et al: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419-1426, 2008
9. Dent R, Trudeau M, Pritchard KI, et al: Triplenegative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007 (Pubitemid 47219710)
10. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
11. Nishimura R, Arima N: Is triple negative a prognostic factor in breast cancer? Breast Cancer 15:303-308, 2008
12. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: A population-based study from the California cancer Registry. Cancer 109:1721-1728, 2007 (Pubitemid 46668532)
13. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006 (Pubitemid 46631305)
14. Freedman GM, Anderson PR, Li T, et al: Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946-951, 2009
15. Voduc KD, Cheang MC, Tyldesley S, et al: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691
16. Gabos Z, Thoms J, Ghosh S, et al: The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 124:187-194, 2010
17. Albert JM, Gonzalez-Angulo AM, Guray M, et al: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 77:1296-1302
18. Lesniak D, Xu Y, Deschênes J, et al: Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 69: 8620-8628, 2009
19. Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658-5663, 2006 (Pubitemid 46631306)
20. Levine M: Clinical practice guidelines for the care and treatment of breast cancer: Adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update). CMAJ 164:644-646, 2001
21. Truong PT, Olivotto IA, Whelan TJ, et al: Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional postmastectomy radiotherapy. CMAJ 170:1263-1273, 2004
22. Whelan T, Olivotto I, Levine M: Clinical practice guidelines for the care and treatment of breast cancer: Breast radiotherapy after breast-conserving surgery (summary of the 2003 update). CMAJ 168:437-439, 2003
23. Shenkier T, Weir L, Levine M, et al: Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 170:983-994, 2004
24. Reis-Filho JS, Tutt AN: Triple negative tumours: A critical review. Histopathology 52:108-118, 2008 (Pubitemid 350265179)
25. Colleoni M, Cole BF, Viale G, et al: Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28:2966-2973, 2010
26. Carlson RW, Allred DC, Anderson BO, et al: Breast cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:122-192, 2009
27. Jagsi R, Raad RA, Goldberg S, et al: Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 62:1035-1039, 2005 (Pubitemid 40884415)
28. Truong PT, Lesperance M, Culhaci A, et al: Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 62:175-182, 2005 (Pubitemid 40591940)
29. Kaplan HG, Malmgren JA, Atwood M: T1N0 triple negative breast cancer: Risk of recurrence and adjuvant chemotherapy. Breast J 15:454-460, 2009
30. Crabb SJ, Cheang MC, Leung S, et al: Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 8:249-256, 2008 (Pubitemid 351962146)
31. Foulkes WD, Grainge MJ, Rakha EA, et al: Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 117:199-204, 2009